Description

Best Quality JWH-051 Available

What is JWH-051?

JWH-051 is an analgesic compound  which is a cannabinoid agonist with it  chemical structure is closely similar to that of the potent cannabinoid agonist HU-210, with the only difference being the removal of the hydroxyl group at position 1 of the aromatic ring. JWH-051 for sale

However it retains high affinity for the CB₁ receptor, but is a much stronger agonist for CB₂, with a Ki value of 14nM at CB₂ vs 19nM at CB₁.

It is one of the first CB₂-selective ligands developed, although its selectivity for CB₂ is modest compared to newer compounds such as HU-308.

It also have  similar effects to other cannabinoid agonists such as sedation and analgesia, but with a relatively strong anti-inflammatory effect due to its strong activity at CB_2.

Product Information,JWH-051 for sale

WH-015 was still effective in eliciting its anti-inflammatory effects despite the absence of CB2, suggesting the role of non-canonical.

Computational studies using molecular docking and molecular dynamics simulations showed that JWH-105 favorably binds to glucocorticoid receptor (GR).

Furthermore, knockdown of GR using siRNA abrogated JWH-015’s ability to reduce IL-1β-induced IL-6 and IL-8 production. In vivo, administration of JWH-015 (5 mg/kg, daily i.p. for 7 days at the onset of arthritis) significantly ameliorated AIA in rats.

Pain assessment studies using von Frey method showed a marked antinociception in AIA rats treated with JWH-015.

In addition, JWH-015 treatment inhibited bone destruction as evident from micro-CT scanning and bone analysis on the harvested joints.

Overall, our findings suggest that CB2 agonist JWH-015 elicits anti-inflammatory effects partly through GR.

This compound could  be test as an adjunct therapy for the management of pain and tissue destruction as a non-opioid for RA.

However, pain management therapies are some of the most needed and demanded. A recent survey of 1,004 RA patients in the U.S.